PE20152003A1 - Reduccion del riesgo de la enfermedad autoinmune - Google Patents

Reduccion del riesgo de la enfermedad autoinmune

Info

Publication number
PE20152003A1
PE20152003A1 PE2015001891A PE2015001891A PE20152003A1 PE 20152003 A1 PE20152003 A1 PE 20152003A1 PE 2015001891 A PE2015001891 A PE 2015001891A PE 2015001891 A PE2015001891 A PE 2015001891A PE 20152003 A1 PE20152003 A1 PE 20152003A1
Authority
PE
Peru
Prior art keywords
related diseases
risk
nutritional composition
reducing
autoimmune disease
Prior art date
Application number
PE2015001891A
Other languages
English (en)
Inventor
Gabriele Gross
Dirk Hondmann
Tol Erick A F Van
Marieke H Schoemaker
Teartse Tim Lambers
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of PE20152003A1 publication Critical patent/PE20152003A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION NUTRICIONAL QUE COMPRENDE PEPTIDOS SELECIONADOS A PARTIR DE UN HIDROLIZADO DE CASEINA, QUE ADEMAS COMPRENDE UNA FASE DE GRASA O LIPIDO, Y UNA FUENTE DE PROTEINA. DE PREFERENCIA, EL HIDROLIZADO CONSISTE EN PEPTIDOS CON UN PESO MOLECULAR DE MAS DE 500 Da. ADICIONALMENTE, DICHA COMPOSICION COMPRENDE UNO O MAS DE HIDRATOS DE CARBONO, ACIDOS NUCLEICOS, LIPIDOS, MINERALES, NUTRIENTES ANABOLICOS, VITAMINAS, ANTIOXIDANTES, CEPAS BACTERIANAS PROBIOTICAS Y AGENTES LIPOTROPICOS. LA COMPOSICION NUTRICIONAL DE LA INVENCION ES UTIL PARA REDUCIR EL RIESGO DE ENFERMEDADES AUTOINMUNES TALES COMO DIABETES TIPO 1, ENFERMEDAD DE CROHN, COLITIS ULCEROSA, SINDROME METABOLICO, ENFERMEDADES RELACIONADAS CON HLA-DQ8, ENFERMEDADES RELACIONADAS CON HLA-DQ2, Y ENFERMEDAD CELIACA
PE2015001891A 2013-03-15 2014-03-11 Reduccion del riesgo de la enfermedad autoinmune PE20152003A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/839,212 US9289461B2 (en) 2013-03-15 2013-03-15 Reducing the risk of autoimmune disease

Publications (1)

Publication Number Publication Date
PE20152003A1 true PE20152003A1 (es) 2016-01-29

Family

ID=50483516

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001891A PE20152003A1 (es) 2013-03-15 2014-03-11 Reduccion del riesgo de la enfermedad autoinmune

Country Status (15)

Country Link
US (1) US9289461B2 (es)
EP (1) EP2968438A1 (es)
CN (1) CN105073126A (es)
AR (1) AR095335A1 (es)
AU (1) AU2014237022A1 (es)
BR (1) BR112015017909A2 (es)
CA (1) CA2905817A1 (es)
HK (1) HK1216994A1 (es)
MX (1) MX2015011927A (es)
PE (1) PE20152003A1 (es)
PH (1) PH12015502100B1 (es)
RU (1) RU2015139557A (es)
SG (1) SG11201505692QA (es)
TW (1) TW201521756A (es)
WO (1) WO2014150566A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251928B2 (en) 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
US20170020950A1 (en) * 2015-07-23 2017-01-26 Mead Johnson Nutrition Company Methods for modulating kinases
US11540550B2 (en) 2016-05-11 2023-01-03 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
CN117384270B (zh) * 2023-10-13 2024-07-16 华南理工大学 一种酪蛋白源dpp-iv抑制六肽及其制备方法与应用
WO2026003044A1 (en) * 2024-06-25 2026-01-02 Ntd Labs, S.L. Casein hydrolysate for treating crohn's disease

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2064092C2 (de) 1970-12-28 1983-06-01 Bayer Ag, 5090 Leverkusen Inhibitoren für Glykosidhydrolasen aus Actinomyceten
US3937817A (en) 1973-02-28 1976-02-10 Bayer Aktiengesellschaft Pharmaceutical compositions containing a saccharase inhibitor
GB1475624A (en) 1974-07-22 1977-06-01 Toyama Chemical Co Ltd Polypeptide
FR2474829B1 (fr) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech Procede de traitement d'une matiere a base de caseine contenant des phosphocaseinates de cations monovalents ou leurs derives, produits obtenus et applications
FR2474828B1 (fr) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech Procede de traitement d'une matiere premiere a base de caseine, contenant des phosphocaseinates de cations bivalents, produits obtenus et application
US4491589A (en) 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
DK589785A (da) 1985-12-18 1987-06-19 Samuelsson Ernst Gunnar Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet
IT1190349B (it) 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
FR2608050B1 (fr) 1986-12-15 1990-04-13 Bellon Labor Sa Roger Procede de preparation d'un melange peptidique riche en di- et tri-peptides, utilisable notamment en nutrition artificielle et en dietetique, melange ainsi obtenu, et utilisation de ce melange en nutrition artificielle et en dietetique
US5230902A (en) 1988-04-29 1993-07-27 Immunotec Research Corporation Undenatured whey protein concentrate to improve active systemic humoral immune response
US5102871A (en) 1989-04-24 1992-04-07 Kyowa Hakko Kogyo Co., Ltd. Nutrient composition
FI904074A7 (fi) 1989-08-28 1991-03-01 Milupa Ag Optimoidun aminohappokoostumuksen omaavat proteiini-, peptidi- ja aminohapposeokset sekä niiden käyttö keskosten ja rintalasten ravinnon sekä äidinmaidon lisäaineiden valmistamiseksi
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
PH30997A (en) 1990-03-12 1997-12-23 Ciba Geigy Antipathologenically effective compositions comprising lytic peptides and hydrolytic enzymes.
CA2101274C (en) 1991-01-24 1998-12-15 David J. Kyle Microbial oil mixtures and uses thereof
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
GB9310472D0 (en) 1993-05-20 1993-07-07 Univ Warwick Phenylalanine-free protein and dna coding thereof
GB9312369D0 (en) 1993-06-16 1993-07-28 Sandoz Nutrition Ltd Organic compounds
US5405637A (en) * 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
US5723446A (en) 1993-12-23 1998-03-03 Nestec Ltd. Enteral formulation designed for optimized nutrient absorption and wound healing
US5714472A (en) 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
US5605893A (en) 1994-03-15 1997-02-25 Children's Hospital Of Los Angeles Method of using a therapeutic food composition to diminish blood sugar fluctuations in diabetic patients
US5643880A (en) 1994-05-26 1997-07-01 Abbott Laboratories Product for inhibition of attachment of H. influenzae to human cells
CA2204245C (en) 1994-11-04 2008-07-22 Robert Bartlett Elliott Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
US5821217A (en) 1995-10-27 1998-10-13 Beth Israel Deaconess Medical Center, Inc. Enteral formulation: low in fat and containing protein hydrolysates
IT1277964B1 (it) 1995-12-27 1997-11-12 Biosistema Di Pier Luigi Spara Prodotto derivato da latte, sostanzialmente esente da betacaseina di mammifero non umano e relativo uso
KR100194074B1 (ko) 1996-02-21 1999-06-15 박종헌 글루텐 펩타이드를 유효성분으로 포함하는 미네랄 흡수 촉진제
CA2260892A1 (en) 1996-07-17 1998-01-22 Nicada, Inc. Appetite suppression
KR100221124B1 (ko) 1996-09-23 1999-10-01 한상기 신규한 카제인 및 그 제조방법
NL1005037C2 (nl) 1997-01-17 1998-07-20 Nl Zuivelonderzoek Inst Werkwijze voor het selectief afbreken van melkeiwit, in het bijzonder voor het selectief hydrolyseren van caseïne/caseïnaat in aanwezigheid van andere melkeiwitten, in het bijzonder wei-eiwitten.
CA2340223A1 (en) 1998-08-12 2000-02-24 Morinaga Milk Industry Co., Ltd. Nutritional compositions for preventing or treating hyperlipoproteinemia
JP2000063284A (ja) * 1998-08-21 2000-02-29 Terumo Corp 炎症性腸疾患再燃防止剤
US6077558A (en) 1998-12-23 2000-06-20 Bristol-Myers Squibb Company Elemental nutritional products
US6905702B1 (en) 1999-11-08 2005-06-14 Children's Hospital Los Angeles Methods for regulating blood glucose and appetite suppression in type 2 diabetics
GB9927603D0 (en) 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
EP1112693B1 (en) 1999-12-30 2006-03-22 Kerry Group Services Ltd Composition comprising carbohydrate and peptide material and its use as an energy supplement after or during physical exercise or as a metabolic nutrient for oral consumption
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
US6207638B1 (en) 2000-02-23 2001-03-27 Pacifichealth Laboratories, Inc. Nutritional intervention composition for enhancing and extending satiety
IL134830A0 (en) 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
US7666996B2 (en) 2000-03-01 2010-02-23 Peptera Pharmaceuticals Ltd Casein derived peptides and uses thereof
TWI268138B (en) 2000-05-11 2006-12-11 Kanebo Seiyaku Ltd Composition containing peptide and electrolyte excretion enhancing substance, and food containing the same
EP1298204B1 (en) 2000-06-28 2007-04-04 Fuji Nihon Seito Corporation Novel inulin synthase and process for producing inulin by using the same
GB0016189D0 (en) 2000-06-30 2000-08-23 Pepsyn Ltd Cosmetic composition
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
AU1142001A (en) 2000-10-19 2002-04-29 Dsm N.V. Protein hydrolysates
US20050019372A1 (en) 2001-07-10 2005-01-27 Barbara E Corkey Modified-fat nutritional products useful preventing or treating obesity
RU2292155C2 (ru) 2001-07-18 2007-01-27 ДСМ Ай Пи ЭССЕТС Б.В. Способ гидролиза молочных белков
DE10149668A1 (de) 2001-10-09 2003-04-10 Numico Res B V Insulinmimetische Aminosäuresequenzen
JP2003137804A (ja) 2001-10-31 2003-05-14 Morinaga Milk Ind Co Ltd インターロイキン−１８誘導剤
NZ533544A (en) 2001-11-21 2005-02-25 Morinaga Milk Industry Co Ltd Novel peptide having angiotensin convertase inhibitory effect
EP1359157A1 (en) 2002-04-29 2003-11-05 Société des Produits Nestlé S.A. Metallo-proteinase inhibitory agent
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
ES2540926T3 (es) 2002-06-04 2015-07-14 Dsm Ip Assets B.V. Hidrolizado de proteínas rico en tripéptidos
FR2841473B1 (fr) 2002-06-27 2004-09-17 Ingredia Utilisation d'au moins un peptide de la caseine s2 a activite inhbitrice de l'enzyme de conversion de l'engiotensine i pour la preparation de medicaments, d'aliments et de complements alimentaires
AU2003264256A1 (en) 2002-09-04 2004-03-29 Dsm Ip Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
TWI317636B (en) 2002-11-22 2009-12-01 Meiji Dairies Corp Nutritional compositions for liver disease patients or for patients underhigh levels of invasive stress
CA2481489A1 (en) 2002-11-29 2004-06-17 Morinaga Milk Industry Co., Ltd. Cysteine protease inhibitor
EP2141235B1 (en) 2002-12-29 2014-06-11 Toudai Tlo, Ltd. Adiponectin receptor and gene coding for the same
ZA200507880B (en) 2003-05-05 2006-12-27 Unilever Plc Hydrolysed casein product comprising tripeptides IPP and/or VPP
HUE044812T2 (hu) 2003-09-23 2019-11-28 Dsm Ip Assets Bv Prolinspecifikus endoproteázok alkalmazása peptidek és fehérjék hidrolízisére
SG152271A1 (en) 2003-10-24 2009-05-29 Nutricia Nv Immunemodulating oligosaccharides
BE1015863A6 (nl) 2004-01-19 2005-10-04 Huybrechts Lucas Anticariogene proteinen & peptiden & sacchariden.
AU2005207891B2 (en) 2004-01-28 2010-04-01 Andromeda Biotech Ltd. Hsp therapy in conjunction with a low antigenicity diet
EP1568707A1 (en) 2004-02-26 2005-08-31 Puleva Biotech, S.A. Antihypertensive peptides from casein hydrolysates
EA200601575A1 (ru) 2004-03-01 2007-06-29 Пептера Фармасьютикалс Лтд. Казеиновые пептиды и их терапевтическое применение
EP1753443A1 (en) 2004-05-27 2007-02-21 Campina Nederland Holding B.V. Use of protein hydrolysates for the manufacture of a medicament for prophylaxis and/or treatment of a dpp-iv mediated condition
DE102004040452A1 (de) 2004-08-20 2006-02-23 N.V. Nutricia Peptidgemisch
KR100560127B1 (ko) 2004-09-04 2006-03-13 한국기초과학지원연구원 인산화 단백질 분석용 겔-내 표지화 및 겔-내 단리 방법및 이를 이용한 단백질의 인산화 위치 동정 방법
US20080108548A1 (en) 2004-11-12 2008-05-08 N.V. Nutricia Food Composition For Rapidly Attenuating Inflammatory Responses
KR101331777B1 (ko) 2004-12-23 2013-11-21 캄피나 네덜란드 홀딩 베.붸. Ｄｐｐ-ｉｖ를 억제하는 펩타이드가 풍부한 단백질가수분해물 및 이의 용도
BRPI0606687A2 (pt) 2005-01-18 2009-07-14 Dsm Ip Assets Bv composições nutracêuticas
ES2337495T3 (es) 2005-02-03 2010-04-26 Dsm Ip Assets B.V. Composiciones que comprenden galato de epigalocatecina e hidrolizado de proteina.
ZA200706125B (en) 2005-02-09 2008-09-25 Unilever Plc Food products comprising hydrolysed milk solids with improved taste
EP1874140B1 (en) 2005-04-28 2011-02-09 Unilever N.V. Peptides having a health benefit and compositions comprising them
BRPI0610330A2 (pt) 2005-04-28 2010-06-15 Dsm Ip Assets B.V. composições nutracêuticas.
US20090074893A1 (en) 2005-04-29 2009-03-19 Campina Nederland Holding B.V. Antiviral peptides
ES2319475B1 (es) 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
CN101212911B (zh) 2005-07-01 2012-12-05 努特里希亚公司 含水解的蛋白质的婴儿营养品
GB0523806D0 (en) 2005-11-23 2006-01-04 Micromass Ltd Mass spectrometer
JP2009517464A (ja) 2005-11-30 2009-04-30 カンピーナ ネーダーランド ホールディング ビー．ブイ． グルカゴン様ペプチド１の活性を増強するタンパク質加水分解物の使用
WO2008054192A1 (en) 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
EP1800675B1 (en) 2005-12-23 2011-05-18 N.V. Nutricia Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
JP5096173B2 (ja) 2006-02-09 2012-12-12 カルピス株式会社 経口摂取用関節リウマチ抑制剤
US20090318366A1 (en) 2006-03-22 2009-12-24 Dsm Ip Assets B.V. Cholesterol lowering protein hydrolysates
EP2003991A1 (en) 2006-04-12 2008-12-24 DSM IP Assets B.V. Novel nutraceutical compositions
CA2649842C (en) 2006-04-21 2015-02-17 Meiji Seika Kaisha, Ltd. Composition containing peptide as active ingredient
AU2007244352B2 (en) 2006-04-28 2013-09-26 Megmilk Snow Brand Co., Ltd. Peptide
KR20080003637A (ko) 2006-07-03 2008-01-08 한상기 다이어트효과가 우수한 기능성 유산균발효조성물
ES2525223T3 (es) 2006-08-04 2014-12-19 Shs International Ltd. Fórmula sin proteínas
EP2049091B1 (en) 2006-08-09 2010-12-29 DSM IP Assets B.V. Casein complexes
NL1032840C2 (nl) 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
NL1033521C2 (nl) 2007-03-08 2008-09-09 Friesland Brands Bv Kindervoedingen met geoptimaliseerde aminozuursamenstelling.
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
CA2688293A1 (en) 2007-05-25 2008-12-04 Childrens's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
WO2008153429A2 (en) 2007-06-11 2008-12-18 Uniwersytet Jagiellonski A protease from staphylococcus aureus, particularly spia or spib, peptides it recognises and their use
AU2008297541A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
JP5620106B2 (ja) 2007-10-24 2014-11-05 株式会社糖鎖工学研究所 増強されたエフェクター機能を有するポリペプチド
US20110190215A1 (en) * 2008-05-15 2011-08-04 Regen Therapeutics Plc Therapeutic use of peptides
US8859210B2 (en) 2008-10-17 2014-10-14 Mead Johnson Nutrition Company Method for identifying allergenic proteins and peptides
JP5735734B2 (ja) 2009-04-16 2015-06-17 雪印メグミルク株式会社 脂質代謝改善剤
EP2253324A1 (en) 2009-04-30 2010-11-24 Consejo Superior De Investigaciones Cientificas Use of a casein-derived peptide and compositions thereof as antihypertensive
EP2295535A1 (en) 2009-09-11 2011-03-16 Mead Johnson Nutrition Company Probiotic material
ES2524067T3 (es) 2009-12-04 2014-12-03 Mjn U.S. Holdings Llc Formulación nutricional que comprende un hidrolizado que contiene péptidos de leche de vaca y/o péptidos derivados del mismo para la inducción de tolerancia
NZ601141A (en) 2010-01-19 2014-07-25 Abbott Lab Nutritional formulas containing synbiotics
AU2011221270A1 (en) 2010-02-24 2012-09-13 Morinaga Milk Industry Co.,Ltd. Therapeutic agent for eating disorders
EP2514435A1 (en) 2011-04-19 2012-10-24 Nestec S.A. Infant formula for use in the prevention of cardiovascular diseases

Also Published As

Publication number Publication date
EP2968438A1 (en) 2016-01-20
AR095335A1 (es) 2015-10-07
AU2014237022A1 (en) 2015-08-13
WO2014150566A1 (en) 2014-09-25
BR112015017909A2 (pt) 2017-11-21
RU2015139557A (ru) 2017-05-02
SG11201505692QA (en) 2015-08-28
US9289461B2 (en) 2016-03-22
MX2015011927A (es) 2015-12-01
US20140274892A1 (en) 2014-09-18
HK1216994A1 (zh) 2016-12-16
PH12015502100A1 (en) 2016-01-18
CN105073126A (zh) 2015-11-18
CA2905817A1 (en) 2014-09-25
TW201521756A (zh) 2015-06-16
PH12015502100B1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
PE20152003A1 (es) Reduccion del riesgo de la enfermedad autoinmune
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
PE20151765A1 (es) Formulas a base de hidrolizado de aminoacido y proteina con un sistema estable de emulsion
BR112012031183A2 (pt) líquidos nutricionais substancialmente claros compreendendo proteína de cálcio hmb e solúvel
BR112017014580A8 (pt) Método para obter um isolado peptídico a partir de uma biomassa de microalgas enriquecidas com proteína
AR091422A1 (es) Analogos peptidicos de la exendina 4
MX2016006049A (es) Mimeticos de calcitonina para tratar enfermedades y trastornos.
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
MX2015013590A (es) Sistemas y metodos para la produccion dirigids de una proteina terapeutica dentro de una celula objetivo.
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
PE20150201A1 (es) Proteinas del factor 21 de crecimiento del fibroblasto
PE20171076A1 (es) Composicion que contiene quitina y proteinas digeribles
AR082422A1 (es) Composicion detergente liquida
CR20170197A (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros
UY35740A (es) Análogos de amilina
PE20150190A1 (es) Formulacion farmaceutica
BR112015025733A2 (pt) composição compreendendo uma combinação de um ex-trato de sabugueiro e uma estirpe de lactobacillus rhamnosus
BR112015027540A2 (pt) ácido graxo de resina líquida
BR112016011489A2 (pt) composição nutricional pediátrica com peptídeos do leite para crescimento e desenvolvimento saudável
BR112015009344A2 (pt) produto nutricional líquido com hmb, alto teor de proteína e baixa viscosidade
BR112015005933A2 (pt) composição nutricional para mulher grávida com um perfil benéfico de glicose e insulina
MX373270B (es) Composiciones y metodos para mejorar el rendimiento del ejercicio.
MX380349B (es) Expresion de un anticuerpo de cadena sencilla contra la salmonella en lactobacillus

Legal Events

Date Code Title Description
FA Abandonment or withdrawal